Coronavirus vaccine - Beijing Institute of Biological Products/Wuhan Institute of Biological Products
Alternative Names: 2019-CoV - Wuhan Institute of Biological Products; BBIBP-CorV - Inactivated SARS-CoV-2 vaccine; BBIBP-CorV Vaccine; COVAX; COVID-19 Vaccine - Sinopharm; Inactivated COVID-19 vaccine - Wuhan Institute of Biological Products; SARS-CoV-2 vaccine - Wuhan Institute of Biological Products; Sinopharm CNBG COVID-19 vaccine; Vero cell - Wuhan Institute of Biological ProductsLatest Information Update: 12 Dec 2025
At a glance
- Originator Beijing Institute of Biological Products; Wuhan Institute of Biological Products
- Developer Beijing Institute of Biological Products; China National Biotec Group; Sinopharm
- Class COVID-19 vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - COVID 2019 infections
Highest Development Phases
- Registered COVID 2019 infections
Most Recent Events
- 12 Dec 2025 Cornonavirus vaccine is still registered for COVID-2019 infections (Prevention) in Bahrain (Parenteral)
- 12 Dec 2025 Cornonavirus vaccine is still registered for COVID-2019 infections (Prevention) in Egypt (Parenteral)
- 12 Dec 2025 Cornonavirus vaccine is still registered for COVID-2019 infections (Prevention) in Jordan (Parenteral)